Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
October 30, 2024 13:42 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing...
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
October 28, 2024 21:15 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing...
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
October 28, 2024 16:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing...
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
October 22, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
October 15, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
October 07, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
September 12, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
August 21, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
August 14, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...